Novel monoclonal antibody targets CD20 in relapsed NHLHemOncTodaySAN DIEGO — The novel anti-CD20 monoclonal antibody obinutuzumab was linked to better response rates than rituximab in a cohort of patients with relapsed non-Hodgkin's lymphoma, acc…
Celgene, GELA Initiate RELEVANCE Phase III Study In Follicular LymphomaRTT NewsThe combination of REVLIMID and rituximab, also referred to as the R-squared or R2 regimen pioneered by Nathan Fowler, MD and colleagues at the MD Anderson Cancer Center, Ho…
Adding rituximab to chemotherapy regimens improves outcomes for AIDS-related …aidsmapThe addition of rituximab to chemotherapy regimens for the treatment of AIDS-related lymphomas improves both overall survival and progression-free survival, German i…
REVLIMID¬Æ Evaluated in Combination with Rituximab as a Potential Treatment …PharmiWeb.com (press release)Celgene International S√†rl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced results from an investigational study evaluatin…
Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO …MarketWatch (press release)The presentation by Idera scientists, entitled "IMO-4200, a novel TLR7 and TLR8 dual agonist, enhances antitumor effect of ofatumumab, ritux…
Final Phase II Data Evaluating REVLIMID® and Rituximab in Patients with …Business Wire (press release)In the study, 59 patients received rituximab 375 mg/m 2 intravenously weekly for four weeks in cycle one, and then once every four weeks during cyc…
MD News (press release)Early PET Predicts Survival Outcomes in B-Cell LymphomaMD News (press release)An interim [ 18 F] fluorodeoxyglucose positron emission tomography can effectively predict the survival outcomes of patients with diffuse large B-cell …
MD NewsEarly PET Predicts Survival Outcomes in B-Cell LymphomaDoctors LoungeAn interim [ 18 F] fluorodeoxyglucose positron emission tomography can effectively predict the survival outcomes of patients with diffuse large B-cell lymphoma after two cycles…
REVLIMID(R) Evaluated in Combination with Rituximab as a Potential Treatment …MarketWatch (press release)The multicenter phase II study enrolled 69 patients and evaluated the efficacy and safety of combination therapy with lenalidomide and rituximab …
ASH: Obinutuzumab Bests Rituximab in Patients With Relapsed Non-Hodgkin LymphomaCancer NetworkSAN DIEGO—Obinutuzumab (GA101) achieved higher response rates than rituximab in the first head-to-head trial of the two biologic agents in patients with rel…